Clinical observation of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum BNP level

中国基层医药 Pub Date : 2020-03-01 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.05.017

Zhidi Li

{"title":"Clinical observation of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum BNP level","authors":"Zhidi Li","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.017","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the clinical efficacy of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum B-type natriuretic peptide(BNP). \n \n \nMethods \nFrom December 2017 to February 2019, 102 patients with heart failure admitted to Lyucheng Cardiovascular Hospital of Zhejiang Province were selected and divided into control group and treatment group according to random number table method, with 51 cases in each group.The control group was treated with routine treatment, while the treatment group was treated with sakubattral and valsartan sodium tablets on the basis of routine treatment.Both two groups were treated for 12 weeks.The heart function[including left ventricular ejection fraction(LVEF), cardiac output per stroke(SV) and left ventricular end-diastolic diameter(LVEDD)], serum BNP, 6-minute walking distance(6MWD) and quality of life were compared between the two groups before and after treatment. \n \n \nResults \nThe total effective rate of the treatment group was 94.12%(48/51), which was higher than 72.55%(37/51) of the control group, the difference was statistically significant(χ2=8.541, P<0.05). After treatment, the LVEF[(60.28±6.97)%] and SV[(78.91±4.23)mL] in the treatment group were higher than those in the control group[(52.31±4.56)% and (71.35±6.74)mL], while the LVEDD in the trentment group [(54.89±5.26)mm]was lower than that in the control group[(61.74±4.80)mm], the differences were statistically significant(t=6.834, 6.785, 6.870, all P<0.05). After treatment, the serum BNP level in the treatment group[(164.32±14.39)ng/L] was lower than that in the control group[(248.96±23.15)ng/L], while the 6MWD in the trentment group [(353.27±42.26)m] was higher than that in the control group[(273.21±34.47)m], the differences were statistically significant (t=22.175, 10.484, all P<0.05). After treatment, the MLHFQ score in the treatment group[(27.83±5.41)points] was lower than that in the control group[(41.98±7.64)points], the difference was statistically significant(t=10.794, P<0.05). \n \n \nConclusion \nSakubattral and valsartan sodium tablets has good clinical efficacy in treating heart failure, it can improve cardiac function and reduce serum BNP level, which is worthy of clinical application. \n \n \nKey words: \nHeart Failure; Sakubattral and valsartan sodium tablets; Heart function tests; Stroke volume; Natriuretic peptide, brain; Quality of Life","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 1","pages":"586-590"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Objective To investigate the clinical efficacy of sakubattral and valsartan sodium tablets in the treatment of heart failure and its effect on cardiac function and serum B-type natriuretic peptide(BNP). Methods From December 2017 to February 2019, 102 patients with heart failure admitted to Lyucheng Cardiovascular Hospital of Zhejiang Province were selected and divided into control group and treatment group according to random number table method, with 51 cases in each group.The control group was treated with routine treatment, while the treatment group was treated with sakubattral and valsartan sodium tablets on the basis of routine treatment.Both two groups were treated for 12 weeks.The heart function[including left ventricular ejection fraction(LVEF), cardiac output per stroke(SV) and left ventricular end-diastolic diameter(LVEDD)], serum BNP, 6-minute walking distance(6MWD) and quality of life were compared between the two groups before and after treatment. Results The total effective rate of the treatment group was 94.12%(48/51), which was higher than 72.55%(37/51) of the control group, the difference was statistically significant(χ2=8.541, P<0.05). After treatment, the LVEF[(60.28±6.97)%] and SV[(78.91±4.23)mL] in the treatment group were higher than those in the control group[(52.31±4.56)% and (71.35±6.74)mL], while the LVEDD in the trentment group [(54.89±5.26)mm]was lower than that in the control group[(61.74±4.80)mm], the differences were statistically significant(t=6.834, 6.785, 6.870, all P<0.05). After treatment, the serum BNP level in the treatment group[(164.32±14.39)ng/L] was lower than that in the control group[(248.96±23.15)ng/L], while the 6MWD in the trentment group [(353.27±42.26)m] was higher than that in the control group[(273.21±34.47)m], the differences were statistically significant (t=22.175, 10.484, all P<0.05). After treatment, the MLHFQ score in the treatment group[(27.83±5.41)points] was lower than that in the control group[(41.98±7.64)points], the difference was statistically significant(t=10.794, P<0.05). Conclusion Sakubattral and valsartan sodium tablets has good clinical efficacy in treating heart failure, it can improve cardiac function and reduce serum BNP level, which is worthy of clinical application. Key words: Heart Failure; Sakubattral and valsartan sodium tablets; Heart function tests; Stroke volume; Natriuretic peptide, brain; Quality of Life

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

缬沙坦钠片治疗心力衰竭的临床观察及其对心功能和血清BNP水平的影响

目的观察沙司妥缬沙坦钠片治疗心力衰竭的临床疗效及对心功能和血清b型钠素(BNP)的影响。方法选取2017年12月~ 2019年2月在浙江省柳城心血管医院住院的心力衰竭患者102例，按随机数字表法分为对照组和治疗组，每组51例。对照组患者给予常规治疗，治疗组患者在常规治疗的基础上给予佐古曲特、缬沙坦钠片治疗。两组均治疗12周。比较两组患者治疗前后心功能[包括左室射血分数(LVEF)、单次搏心输出量(SV)、左室舒张末期内径(LVEDD)]、血清BNP、6分钟步行距离(6MWD)及生活质量。结果治疗组总有效率为94.12%(48/51)，高于对照组的72.55%(37/51)，差异有统计学意义(χ2=8.541, P<0.05)。治疗后，治疗组LVEF[(60.28±6.97)%]和SV[(78.91±4.23)mL]均高于对照组[(52.31±4.56)%和(71.35±6.74)mL]，治疗组LVEDD[(54.89±5.26)mm]低于对照组[(61.74±4.80)mm]，差异均有统计学意义(t=6.834、6.785、6.870，均P<0.05)。治疗后，治疗组血清BNP水平[(164.32±14.39)ng/L]低于对照组[(248.96±23.15)ng/L]，治疗组6MWD[(353.27±42.26)m]高于对照组[(273.21±34.47)m]，差异均有统计学意义(t=22.175、10.484，均P<0.05)。治疗后，治疗组MLHFQ评分[(27.83±5.41)分]低于对照组[(41.98±7.64)分]，差异有统计学意义(t=10.794, P<0.05)。结论沙司妥缬沙坦钠片治疗心力衰竭临床疗效良好，可改善心功能，降低血清BNP水平，值得临床推广应用。关键词:心力衰竭;舒巴楚缬沙坦钠片;心功能检查;中风体积;利钠肽，脑;生活品质

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.